首页 > 市场调查报告书 > 製药

生物製剂

全球细胞免疫治疗市场研究报告 - 2023 年至 2030 年行业分析、规模、份额、增长、趋势和预测

市场调查报告书

商品编码

1342894

全球细胞免疫治疗市场研究报告 - 2023 年至 2030 年行业分析、规模、份额、增长、趋势和预测

Global Cellular Immunotherapy Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2030

出版日期: 2023年08月01日 | 出版商:

Value Market Research | 英文 171 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录图表

预计到2030年，全球细胞免疫治疗市场的市场规模将从2022年的93.5亿美元达到近673.4亿美元，2023-2030年研究期间的复合年增长率为24.53%。

细胞免疫疗法被定义为一种创新的癌症治疗方法，利用我们的免疫系统细胞来消除癌症。细胞免疫治疗方法涉及直接分离免疫细胞并简单地增加其数量，而其他方法则涉及通过基因治疗对免疫细胞进行基因改造，以增强其破坏肿瘤的能力。细胞免疫疗法比旧疗法受到广泛青睐，因为它提供长期的癌症保护，副作用较小，并且已成功治疗不同的癌症，如乳腺癌、前列腺癌、黑色素瘤、肺癌等。细胞免疫疗法是通过将免疫细胞引导至癌症特异性靶标、激活免疫系统在靶标处聚集并触发能够破坏骨髓瘤细胞的免疫反应来进行的。

市场动态：

细胞免疫治疗市场的强劲增长是由多种因素推动的，例如免疫疗法相对于传统疗法的接受度不断提高、生物仿製药的不断出现、对单克隆抗体(mAb) 的需求不断增加以及不断增长的人口中癌症患病率的上升。由于选择细胞免疫疗法作为替代治疗选择的患者生存率提高，细胞免疫疗法的市场将会增长。推动细胞免疫疗法市场增长的其他因素包括医疗保健支出的增加、研发活动的增加、医疗保险的便捷性以及癌症治疗方法技术进步的激增。

该研究报告涵盖波特五力模型、市场吸引力分析和价值链分析。这些工具有助于清晰地了解行业结构并评估全球范围内的竞争吸引力。此外，这些工具还对全球细胞免疫治疗市场的每个细分市场进行了包容性评估。细胞免疫治疗行业的增长和趋势为这项研究提供了整体方法。

区域分析：

本节涵盖区域前景，重点介绍北美、欧洲、亚太地区、拉丁美洲以及中东和非洲细胞免疫治疗市场当前和未来的需求。此外，该报告重点关注所有主要地区各个应用领域的需求、估计和预测。

该研究报告还涵盖了市场主要参与者的全面概况以及对全球竞争格局的深入了解。细胞免疫治疗市场的主要参与者包括百时美施贵宝公司、诺华公司、吉利德科学公司（Kite Pharma）、罗氏公司、默克公司、葛兰素史克公司、阿斯利康公司、辉瑞公司、强生公司。 Johnson、Celyad、Adicet Bio Inc.、Dendreon Pharmaceuticals LLC。本节包含竞争格局的整体视图，包括各种战略发展，例如关键併购、未来产能、合作伙伴关係、财务概况、合作、新产品开发、新产品发布和其他发展。

如果您有任何定制要求，请写信给我们。我们的研究团队可以根据您的需求提供定制报告。

区域展望销售分析
简介销售分析
北美销售分析
- 概述、历史和预测销售分析
- 北美按细分市场销售分析
- 北美按国家/地区销售分析
- 美国销售分析
- 加拿大销售分析
- 墨西哥销售分析
欧洲销售分析
- 概述、历史和预测销售分析
- 欧洲按细分市场销售分析
- 欧洲按国家/地区销售分析
- 英国销售分析
- 法国销售分析
- 德国销售分析
- 意大利销售分析
- 俄罗斯销售分析
- 欧洲其他地区销售分析
亚太地区销售分析
- 概述、历史和预测销售分析
- 亚太地区按细分市场销售分析
- 亚太地区国家/地区销售分析
- 中国销售分析
- 印度销售分析
- 日本销售分析
- 韩国销售分析
- 澳大利亚销售分析
- 亚太地区其他地区销售分析
拉丁美洲销售分析
- 概述、历史和预测销售分析
- 拉丁美洲按细分市场销售分析
- 拉丁美洲按国家/地区销售分析
- 巴西销售分析
- 阿根廷销售分析
- 秘鲁销售分析
- 智利销售分析
- 拉丁美洲其他地区销售分析
中东和非洲销售分析
- 概述、历史和预测销售分析
- 中东和非洲按细分市场销售分析
- 中东和非洲国家销售分析
- 沙特阿拉伯销售分析
- 阿联酋销售分析
- 以色列销售分析
- 南非销售分析
- 中东其他地区和非洲销售分析

第 10 章：细胞免疫治疗公司的竞争格局

细胞免疫治疗市场竞争
伙伴关係/协作/协议
併购
新产品发布
其他发展

第 11 章：公司简介

十大公司股票分析
市场集中度
Bristol-Myers Squibb Company

公司简介
公司收入
产品
最近的发展

Novartis AG

公司简介
公司收入
产品
最近的发展

Gilead Sciences Inc. (Kite Pharma)

公司简介
公司收入
产品
最近的发展

F. Hoffmann-La Roche Ltd

公司简介
公司收入
产品
最近的发展

Merck KGaA

公司简介
公司收入
产品
最近的发展

GlaxoSmithKline plc.

公司简介
公司收入
产品
最近的发展

AstraZeneca

公司简介
公司收入
产品
最近的发展

Pfizer Inc.

公司简介
公司收入
产品
最近的发展

Johnson & Johnson

公司简介
公司收入
产品
最近的发展

Celyad

公司简介
公司收入
产品
最近的发展

Adicet Bio Inc.

公司简介
公司收入
产品
最近的发展

Dendreon Pharmaceuticals LLC

公司简介
公司收入
产品
最近的发展

注意 - 在公司概况中，财务详细信息和近期发展视情况而定，或者如果是私营公司，则可能不包括在内

简介目录图表

Product Code: VMR11219156

The global demand for Cellular Immunotherapy Market is presumed to reach the market size of nearly USD 67.34 BN by 2030 from USD 9.35 BN in 2022 with a CAGR of 24.53% under the study period 2023 - 2030.

Cellular immunotherapy is defined as an innovative cancer treatment approach that uses the cells of our immune system to eliminate cancer. Cellular immunotherapy approaches involve directly isolating immune cells & simply multiplying their numbers, whereas others involve genetically engineered immune cells through gene therapy to enhance their tumor-destroying capabilities. Cellular immunotherapy is widely preferred over old treatment because it provides long-term cancer protection, has lesser side effects, and has been successful in treating different cancers such as breast cancer, prostate cancer, melanoma, lung cancer, and many others. Cellular immunotherapy is performed by directing the immune cells toward cancer-specific targets, activating the immune system to assemble at the target, and triggering an immune response capable of destroying myeloma cells.

MARKET DYNAMICS:

This robust growth of the cellular immunotherapy market is driven by several factors such as increasing acceptance of immunotherapy over conventional therapies, growing emergence of biosimilars, increasing demand for monoclonal antibodies (mAbs), and rising prevalence of cancer among a growing population. The market for cellular immunotherapy will increase due to the increased survival rate of patients who choose it as an alternative treatment option. Other factors propelling the market growth of cellular immunotherapy are an increase in healthcare spending, Increasing R&D activities, easy access to medical insurance, and a surge in technological advancements in cancer treatment methods.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of cellular immunotherapy. The growth and trends of cellular immunotherapy industry provide a holistic approach to this study.

MARKET SEGMENTATION:

This section of the cellular immunotherapy market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Therapy Type

Car T Cell Therapy
Dendritic Cell Therapy
NK Cell Therapy
TIL Therapy
Others

By Indication

B-Cell Malignancies
Prostate Cancer
Liver Cancer
Renal Cell Carcinoma
Others

By End-Use

Hospitals
Cancer Institutes
Others

REGIONAL ANALYSIS:

This section covers the regional outlook, which accentuates current and future demand for the Cellular Immunotherapy market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the cellular immunotherapy market include Bristol-Myers Squibb Company, Novartis AG, Gilead Sciences Inc. (Kite Pharma), F. Hoffmann-La Roche Ltd, Merck KGaA, GlaxoSmithKline plc., AstraZeneca, Pfizer Inc., Johnson & Johnson, Celyad, Adicet Bio Inc., Dendreon Pharmaceuticals LLC. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1 . PREFACE

1.1. Report Description
- 1.1.1. Objective
- 1.1.2. Target Audience
- 1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3 . CELLULAR IMMUNOTHERAPY - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Therapy Type
- 3.7.2 Market Attractiveness Analysis By Indication
- 3.7.3 Market Attractiveness Analysis By End-use
- 3.7.4 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1. List of Raw Materials
- 4.2.2. Raw Material Manufactures List
- 4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1. Direct Marketing
- 4.4.2. Indirect Marketing
- 4.4.3. Marketing Channel Development Trend

5 . IMPACT ANALYSIS OF COVID-19 OUTBREAK

6 . GLOBAL CELLULAR IMMUNOTHERAPY MARKET ANALYSIS BY THERAPY TYPE

6.1 Overview by Therapy Type
6.2 Historical and Forecast Data
6.3 Analysis by Therapy Type
6.4 CAR T Cell Therapy Historic and Forecast Sales by Regions
6.5 Dendritic Cell Therapy Historic and Forecast Sales by Regions
6.6 NK Cell Therapy Historic and Forecast Sales by Regions
6.7 TIL Therapy Historic and Forecast Sales by Regions
6.8 Others Historic and Forecast Sales by Regions

7 . GLOBAL CELLULAR IMMUNOTHERAPY MARKET ANALYSIS BY INDICATION

7.1 Overview by Indication
7.2 Historical and Forecast Data
7.3 Analysis by Indication
7.4 B-cell Malignancies Historic and Forecast Sales by Regions
7.5 Prostate Cancer Historic and Forecast Sales by Regions
7.6 Liver Cancer Historic and Forecast Sales by Regions
7.7 Renal Cell Carcinoma Historic and Forecast Sales by Regions
7.8 Others Historic and Forecast Sales by Regions

8 . GLOBAL CELLULAR IMMUNOTHERAPY MARKET SALES ANALYSIS BY END-USE

8.1 Overview by End-use
8.2 Historical and Forecast Data
8.3 Analysis by End-use
8.4 Hospitals Historic and Forecast Sales by Regions
8.5 Cancer Institutes Historic and Forecast Sales by Regions
8.6 Others Historic and Forecast Sales by Regions

9 . GLOBAL CELLULAR IMMUNOTHERAPY MARKET SALES ANALYSIS BY GEOGRAPHY

9.1. Regional Outlook Sales Analysis
9.2. Introduction Sales Analysis
9.3. North America Sales Analysis
- 9.3.1. Overview, Historic and Forecast Sales Analysis
- 9.3.2. North America By Segment Sales Analysis
- 9.3.3. North America By Country Sales Analysis
- 9.3.4. United State Sales Analysis
- 9.3.5. Canada Sales Analysis
- 9.3.6. Mexico Sales Analysis
9.4. Europe Sales Analysis
- 9.4.1. Overview, Historic and Forecast Sales Analysis
- 9.4.2. Europe by Segment Sales Analysis
- 9.4.3. Europe by Country Sales Analysis
- 9.4.4. United Kingdom Sales Analysis
- 9.4.5. France Sales Analysis
- 9.4.6. Germany Sales Analysis
- 9.4.7. Italy Sales Analysis
- 9.4.8. Russia Sales Analysis
- 9.4.9. Rest Of Europe Sales Analysis
9.5. Asia Pacific Sales Analysis
- 9.5.1. Overview, Historic and Forecast Sales Analysis
- 9.5.2. Asia Pacific by Segment Sales Analysis
- 9.5.3. Asia Pacific by Country Sales Analysis
- 9.5.4. China Sales Analysis
- 9.5.5. India Sales Analysis
- 9.5.6. Japan Sales Analysis
- 9.5.7. South Korea Sales Analysis
- 9.5.8. Australia Sales Analysis
- 9.5.9. Rest Of Asia Pacific Sales Analysis
9.6. Latin America Sales Analysis
- 9.6.1. Overview, Historic and Forecast Sales Analysis
- 9.6.2. Latin America by Segment Sales Analysis
- 9.6.3. Latin America by Country Sales Analysis
- 9.6.4. Brazil Sales Analysis
- 9.6.5. Argentina Sales Analysis
- 9.6.6. Peru Sales Analysis
- 9.6.7. Chile Sales Analysis
- 9.6.8. Rest of Latin America Sales Analysis
9.7. Middle East & Africa Sales Analysis
- 9.7.1. Overview, Historic and Forecast Sales Analysis
- 9.7.2. Middle East & Africa by Segment Sales Analysis
- 9.7.3. Middle East & Africa by Country Sales Analysis
- 9.7.4. Saudi Arabia Sales Analysis
- 9.7.5. UAE Sales Analysis
- 9.7.6. Israel Sales Analysis
- 9.7.7. South Africa Sales Analysis
- 9.7.8. Rest Of Middle East And Africa Sales Analysis

10 . COMPETITIVE LANDSCAPE OF THE CELLULAR IMMUNOTHERAPY COMPANIES

10.1. Cellular Immunotherapy Market Competition
10.2. Partnership/Collaboration/Agreement
10.3. Merger And Acquisitions
10.4. New Product Launch
10.5. Other Developments

11 . COMPANY PROFILES OF CELLULAR IMMUNOTHERAPY INDUSTRY

11.1. Top 10 Company Share Analysis
11.2. Market Concentration Rate
11.3. Bristol-Myers Squibb Company
- 11.3.1. Company Overview
- 11.3.2. Company Revenue
- 11.3.3. Products
- 11.3.4. Recent Developments
11.4. Novartis AG
- 11.4.1. Company Overview
- 11.4.2. Company Revenue
- 11.4.3. Products
- 11.4.4. Recent Developments
11.5. Gilead Sciences Inc. (Kite Pharma)
- 11.5.1. Company Overview
- 11.5.2. Company Revenue
- 11.5.3. Products
- 11.5.4. Recent Developments
11.6. F. Hoffmann-La Roche Ltd
- 11.6.1. Company Overview
- 11.6.2. Company Revenue
- 11.6.3. Products
- 11.6.4. Recent Developments
11.7. Merck KGaA
- 11.7.1. Company Overview
- 11.7.2. Company Revenue
- 11.7.3. Products
- 11.7.4. Recent Developments
11.8. GlaxoSmithKline plc.
- 11.8.1. Company Overview
- 11.8.2. Company Revenue
- 11.8.3. Products
- 11.8.4. Recent Developments
11.9. AstraZeneca
- 11.9.1. Company Overview
- 11.9.2. Company Revenue
- 11.9.3. Products
- 11.9.4. Recent Developments
11.10. Pfizer Inc.
- 11.10.1. Company Overview
- 11.10.2. Company Revenue
- 11.10.3. Products
- 11.10.4. Recent Developments
11.11. Johnson & Johnson
- 11.11.1. Company Overview
- 11.11.2. Company Revenue
- 11.11.3. Products
- 11.11.4. Recent Developments
11.12. Celyad
- 11.12.1. Company Overview
- 11.12.2. Company Revenue
- 11.12.3. Products
- 11.12.4. Recent Developments
11.13. Adicet Bio Inc.
- 11.13.1. Company Overview
- 11.13.2. Company Revenue
- 11.13.3. Products
- 11.13.4. Recent Developments
11.14. Dendreon Pharmaceuticals LLC
- 11.14.1. Company Overview
- 11.14.2. Company Revenue
- 11.14.3. Products
- 11.14.4. Recent Developments